Bellerophon Therapeutics

Bellerophon completes enrollment for phase II trial of INOpulse for PAH

Thursday, June 19, 2014

Bellerophon Therapeutics, a clinical stage biotherapeutics company has completed enrollment of its 80-patient phase II clinical trial of INOpulse for the treatment of pulmonary arterial hypertension (PAH). PAH is a life-threatening, progressive disorder characterized by abnormal constriction of the arteries of the lung, leading to increased blood pressure in the lungs and abnormal strain on the heart’s right ventricle, eventually leading to heart failure.

[Read More]